Loading stock data…
BDX
$152.04+3.10 (+2.08%)
After Hours$152.04+0.00 (+0.00%)· Last close Jun 9
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Becton, Dickinson and Company in the Healthcare sector is trading at $152.04. Wall Street consensus targets $181.23 (13 analysts), implying a +19.2% move over the next 12 months. The stock is currently 19% below its 52-week high of $187.35, remaining 0.8% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +19.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$152.04
Potential Downside
0%
Whystock Fair Value$152.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$181.23+19.2%
Range$150.00 – $225.00
Fundamentals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.32%
ROE
Average efficiency. Growth may require heavy reinvestment.
4.72%
Volume
Today's trading volume
2.21M
Recent News
Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait”
Becton, Dickinson and Company (NYSE:BDX) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending might cause near-term headwind for stocks. When a caller mentioned that they had started a position in the stock, Cramer commented: I like Becton, Dickinson. It is selling frankly at the lowest […]
Is It Smart To Buy Becton, Dickinson and Company (NYSE:BDX) Before It Goes Ex-Dividend?
Becton, Dickinson and Company ( NYSE:BDX ) stock is about to trade ex-dividend in 3 days. The ex-dividend date occurs...
Becton, Dickinson and Company Stock: Is BDX Underperforming the Healthcare Sector?
Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.
Is Avantor (AVTR) Elevating Quality To A Strategic Edge With Its New Regulatory Chief?
In May 2026, Avantor, Inc. appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, giving him global responsibility for quality assurance, quality systems, and regulatory affairs across all of the company’s businesses. Porreca’s extensive background in steering complex global approvals and regulatory transformations at Getinge, Becton Dickinson, C.R. Bard, and Smith+Nephew adds experienced leadership in areas that are increasingly critical for life sciences...
Is Stryker Stock Underperforming the S&P 500?
Despite Stryker’s underperformance relative to the S&P 500 Index over the past year, Wall Street analysts remain highly bullish about the stock’s prospects.